39P Clinical relevance of alterations in cancer (CRAC): A DB for selecting biomarkers for molecularly matched therapy in cancer patients

Multigene testing via NGS can detect multiple genomic alterations (GA). The use of current levels evidence (LOE) requires understanding the functional consequences GA and an extensive literature search have less practical value for narrowing down therapy recommendations if GAs with same LOE are found. For each type GA, depending on gene tumor type, a score from 1 to 10 was assigned independently by group biologists oncologists; average scores were used DB. Scores reflected theoretical estimation percentage patients biomarker that could be matched such therapy, efficacy based expected benefit, quality data, expert opinion; potential obstacles associated access therapy. To test utility DB, we analyzed comprehensive molecular profiling (150+ panels) (CMPR). ranked using ESCAT CRAC. A total 134 genes selected 16 malignancies 2 in (234 total). 2-3 outnumbered 9-10 (36 vs 2%). majority (17 13%) 2-2.5, 3.5-4, within one type. CRAC 208 CMPR (23.5% CRC, 16.3% PAAD, 11% BRCA, 49% - other) 210 analyzed. 64 (31%) reports contained 79 I-III ESCAT, 114 (55%) 131 level IV GA. highest LOE. No had score; IIIA largest range (2-10 1-9). made it possible identify additional targetable 2-4 (45% not present CMPR). Using clinically significant proved more approach compared (each represented ⩾3 scores; BM ⩾2 scores). available at crac.oncoatlas.ru.